BYETTA is not recommended to be taken with insulin.
不推荐百泌达与胰岛素合用。
BYETTA is the first FDA-approved GLP-1 receptor agonist for the treatment of type 2 diabetes.
百泌达是FDA批准的治疗2型糖尿病的首个GLP- 1受体激动剂药物。
BYDUREON and BYETTA belong to the glucagon-like peptide-1 (GLP-1) receptor agonist class of medications.
BYDUREON和百泌达(BYETTA)都属于胰高血糖素样肽(GLP - 1)受体激动剂类药物。
According to another study, diabetics who had a weekly injection of Byetta alone lost 8 pounds after 15 weeks.
另一项研究显示，每周只单独注射一次Byetta的糖尿病患者在十五个星期内减掉了八磅。
It's often used with Byetta, an injectable diabetes drug that delays the movement of food from your stomach into your small intestine, so it may extend fullness and help you to eat less.
它常常和Byetta一起使用，Byetta是一种注射剂，能够延迟食物从胃进入小肠的时间，所以它能够延长饱腹感，对减少食物摄入量有帮助。
The FDA wrote in a separate letter to Lilly and Amylin that, at a medical meeting in Washington in June 2009, company representatives had overstated the ability of Byetta to help patients lose weight.
FDA在分别对礼来公司和Amylin公司的通报中指出，2009年6月在华盛顿举行的一次医学会议上，其公司代表夸大了百泌达有助于患者减轻体重的作用。
The FDA wrote in a separate letter to Lilly and Amylin that, at a medical meeting in Washington in June 2009, company representatives had overstated the ability of Byetta to help patients lose weight.
FDA在分别对礼来公司和Amylin公司的通报中指出，2009年6月在华盛顿举行的一次医学会议上，其公司代表夸大了百泌达有助于患者减轻体重的作用。
应用推荐